These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8813450)
1. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease. Suefuji H; Ogawa H; Yasue H; Imoto N; Sakamoto T; Miyao Y; Kaikita K; Soejima H; Nishiyama K Coron Artery Dis; 1996 Feb; 7(2):167-72. PubMed ID: 8813450 [TBL] [Abstract][Full Text] [Related]
2. Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease. Sano R; Fujino A; Saito T; Takenaka K; Yahata Y; Ogyu A; Toyota T Tohoku J Exp Med; 1993 Apr; 169(4):299-307. PubMed ID: 8248919 [TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effect of niceritrol on plasma lipoprotein-a. Teramoto T; Yamada N; Shimano H; Oka Y; Itakura H; Saito Y; Morisaki N; Shirai K; Ishikawa T; Tada N; Ito H; Yamanouchi T; Matsushima T; Kawakami M; Murase T; Okubo M; Totsuka Y; Kikuchi M Scand J Clin Lab Invest; 1996 Jul; 56(4):359-65. PubMed ID: 8837243 [TBL] [Abstract][Full Text] [Related]
4. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Nakahama H; Nakanishi T; Uyama O; Sugita M; Miyazaki M; Yokokawa T; Okamura K; Tanaka Y; Shirai D Ren Fail; 1993; 15(2):189-93. PubMed ID: 8469786 [TBL] [Abstract][Full Text] [Related]
5. Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia. Tsuruta K; Ogawa H; Yasue H; Sakamoto T; Miyao Y; Tanae H; Kaiga K Coron Artery Dis; 1996 Nov; 7(11):837-42. PubMed ID: 8993942 [TBL] [Abstract][Full Text] [Related]
6. Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a). Yamauchi K; Tanahashi Y; Okada M; Tsuzuki J; Sato A; Abe K; Inagaki H; Agetsuma H; Hattori R; Izawa H Clin Ther; 1995; 17(1):52-9. PubMed ID: 7758061 [TBL] [Abstract][Full Text] [Related]
7. Plasma lipoprotein(a) levels and fibrinolytic activity in patients with unstable angina. Okubo H; Yasue H; Ogawa H; Misumi I; Masuda T; Miyao Y; Sakamoto T Jpn Circ J; 1993 Oct; 57(10):947-54. PubMed ID: 7901435 [TBL] [Abstract][Full Text] [Related]
8. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects]. Xiong X; Zhao S; Wang Z; Lo L; Huang Q Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767 [TBL] [Abstract][Full Text] [Related]
9. Effects of the nicotinic acid analogue niceritrol on lipoprotein Lp(a) and coagulation-fibrinolysis status in patients with chronic renal failure on hemodialysis. Shoji T; Nishizawa Y; Kawasaki K; Tabata T; Matsushita Y; Inoue T; Morii H Nephron; 1997; 77(1):112-3. PubMed ID: 9380227 [No Abstract] [Full Text] [Related]
10. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease. Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039 [TBL] [Abstract][Full Text] [Related]
11. [Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol]. Saika Y; Kodama N; Kimura K; Fujii R; Ohtani H; Mune M; Mimura K; Maeda T; Yukawa S Nihon Jinzo Gakkai Shi; 1999 Jun; 41(4):430-5. PubMed ID: 10441992 [TBL] [Abstract][Full Text] [Related]
12. [Plasma Lp (a) levels and correlation of Lp (a) with fibrinolysis activation in chronic renal failure]. Zhu J; Xiong X; Zhao S; Wang Z; Lou L; Hang Q Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):366-8. PubMed ID: 12080650 [TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676 [TBL] [Abstract][Full Text] [Related]
15. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity]. Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860 [TBL] [Abstract][Full Text] [Related]
16. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Glueck CJ; Glueck HI; Tracy T; Speirs J; McCray C; Stroop D Metabolism; 1993 Feb; 42(2):236-46. PubMed ID: 8474322 [TBL] [Abstract][Full Text] [Related]
17. The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia. Kinoshita M; Mikuni Y; Kudo M; Mori M; Horie E; Teramoto T; Matsushima T J Int Med Res; 2002; 30(3):271-81. PubMed ID: 12166344 [TBL] [Abstract][Full Text] [Related]